Anti-Mouse FGL-1 Antibody (177R4)
Based on 1 publication(s) in Google Scholar
Anti-Mouse FGL-1 Antibody (177R4) is an anti-mouse FGL-1 IgG2a monoclonal antibody. Anti-Mouse FGL-1 Antibody (177R4) can increase CD8+ T cell infiltration. Anti-Mouse FGL-1 Antibody (177R4) enhances the anti-tumor immune effect by blocking FGL1. Anti-Mouse FGL-1 Antibody (177R4) can be used for research on cancer such as lung cancer and breast cancer.
For research use only. We do not sell to patients.
- Purity : 96.31%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Anti-Mouse FGL-1 Antibody (177R4)
More
Biological Activity
Description
Isotype
Rat IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Mouse
IC50 & Target
FGL-1
In Vitro
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Anti-Mouse FGL-1 Antibody (177R4) (100 μg, i.p., on day 6, 10, 14 and 18) significantly inhibit tumor growth combined with PD-1 mAb in female C57BL/6J mice bearing MB49 tumors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5×106 LLC cells injected C57BL/6J mice (4-6 weeks)[1]
-
Dosage:100 μg, combined with PD-1 mAb (100 μg)
-
Administration:Intraperitoneal injection (i.p.), on day 1, 3, 6, 12, 15 and 18
-
Result:Significantly inhibited tumor volume.
Increased CD8+ T cell infiltration within the tumor.
Increased the expression of IFN-γ, TNF-α, and Perforin.
Reduced Ki67 positive cells.
-
Animal Model:1×105 MB49 cells injected female C57BL/6J mice (6-8 weeks)[2]
-
Dosage:100 μg, combined with PD-1 mAb (100 μg)
-
Administration:Intraperitoneal injection (i.p.), on day 6, 10, 14 and 18
-
Result:Significantly inhibited tumor volume and weight.
Significantly increased infiltration of CD8 T cells.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
in vivo FGL-1 blockade; in vitro FGL-1 blockade; Flow cytometry; Immunohistochemistry (paraffin)
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse FGL-1 Antibody (177R4)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Arch Biochem Biophys
Hepassocin drives EGFR-dependent endothelial atherogenic activation via NOX1/ROS amplification and p38 signaling. [Abstract]2026 Jul:781:110820. PMID: 41967236
Purity & Documentation
-
Data Sheet (263 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)